As with additional traditional 3D printing technologies, an important part of bioprinting is the 3D printing material, meaning which there will be worthwhile business opportunities for suppliers of biomatter for 3D printing, just simply as there is with the bioprinting system itself. For which reason, CELLINK and Rooster Bio teamed up to sell CELLINK’s low-priced bioprinter and Rooster Bio’s biomaterials. That’s in addition why bioprinting firm Organovo has today revealed which the commence of their subsidiary Samsara Sciences, Inc., which has begun commercial operations to provide human liver cells for in vivo and in vitro research applications.
Samsara will be the source for primary human liver cells for Organovo, as it explores bioprinting for preclinical and therapeutic tissue research, giving the company a direct donate chain for biomatter. At the same time, Samsara will be able-bodied to provide those cells to Organovo’s customers as a bioprinting materials supplier. This in addition ensures which Organovo can maintain quality control over the materials associated with its operations.
Working closely with Dr. Tatiana Kisseleva, liver cell biology tremendous, and her laboratory at the University of California, San Diego School of Medicine, the subsidiary will start by offering a selection of hepatic stellate cells, which are worthwhile in the development of fatty liver disease, fibrosis, and other widespread illnesses. Samsara’s customers will have access to the subsidiary’s protocols associated with cryopreservation, as well as their complementary services of providing tissue sections, nucleic acids, and gene expression information. And, through their distribution channels, human hepatocytes will in addition be available-bodied.
Dr. Sharon Presnell, President of Samsara Sciences and Chief Technology Officer and Executive Vice President of Research & Development, Organovo, said of the firm’s work, “The Samsara team shares a passion for cells and is dedicated to providing the high-quality, well-characterized cellular reagents which are required to assist the future of biological research and tissue products. Our ultimate vision is to donate a comprehensive portfolio of tissue-specific cells which are tailored for use in the production of the multi-cellular 3D tissues which are poised to change the landscape of drug discovery and regenerative medicine.”
Organovo CEO Keith Murphy adds, “Cell donate and quality are significant to meeting Organovo’s goal to change the shape of medical research and practice, which include our desire to create a bioprinted liver patch for transplant. I’m grateful to the team at Samsara and its key collaborators and scientific advisors for allowing us to develop this high-quality cell source, and to offer it to other researchers through Samsara’s commercial efforts.”
This news assists Gartner’s prediction which bioprinting and medical 3D printing are ramping up towards the hype cycle peak. Such a subsidiary as Samsara is a effortless, even organic development for Organovo and we’ll most likely see even additional such businesses spring up to assist the numerous bioprinting efforts taking place of the world. It’s informative to ponder which Samsara, in Buddhism, represents the endless cycle of existence in which we’re all currently trapped, as an endless donate of human tissues may allow us to, one day, live forever. But will such bioprinting science in addition allow us to escape Samsara and complete Nirvana? Who knows, but you can go over to their website and order a few Primary Human Hepatocytes to have your mind blown.